RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024March 10, 2024 - Cantor Fitzgerald sees another strong year ahead for oncology M&A. Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number.
Remember Cantor Fitzgerald boys and girls ??